Arcosa, Inc. (NYSE:ACA) shareholders approved the proposed acquisition by CRH plc (NYSE:CRH) on September 4. The merger agreement received 39,595,867 votes in favor, compared with 66,113 against and 16,786 abstentions. Approximately 39.7 million shares, representing 80.8% of shares outstanding as of the record date, were present or represented by proxy.
The vote satisfies a major condition for the all-cash transaction. CRH plc (NYSE:CRH) agreed to pay $150 per share, valuing Arcosa, Inc. at an enterprise value of approximately $8.5 billion. The companies continue to expect a first-quarter 2027 closing, subject to required regulatory approvals and other customary conditions.
CRH plc (NYSE:CRH) described the valuation as 11.5 times estimated 2026 adjusted EBITDA, a company-defined non-GAAP measure, including $175 million of targeted annual run-rate cost synergies expected by year three. CRH plc (NYSE:CRH) defines adjusted EBITDA as earnings from continuing operations before interest, taxes, depreciation, depletion and amortization, with exclusions for impairments, divestitures and investments, equity-method results, substantial acquisition costs and specified pension items.
Bull Case
The result removes the principal seller-side approval risk. The merger no longer depends on another shareholder meeting, and support was decisive among the shares represented. Financing appears less exposed than regulatory clearance: CRH plc (NYSE:CRH) plans to use available cash and committed debt financing, while completion is not subject to a financing condition.
The strategic rationale is tangible. Arcosa, Inc. would add 109 quarries and yards, nine asphalt plants, 19 terminals and approximately 35 million tons of 2025 aggregates shipments. CRH plc (NYSE:CRH) expects more than 265 million tons of combined annualized aggregates production. Arcosa, Inc. also brings engineered structures serving grid modernization, electrification and data-center construction.
CRH plc (NYSE:CRH) expects the transaction to be accretive to earnings, margin and cash flow during the first 12 months after completion, before one-off transaction costs. Operational improvements, procurement benefits, greater self-supply and SG&A savings provide the stated sources of the synergy target.
Bear Case
Shareholder approval does not resolve antitrust review. Closing still requires expiration or termination of the waiting period under the Hart-Scott-Rodino Act, approvals in specified jurisdictions, and the absence of a blocking law or court order. The initial outside date is June 21, 2027, but it automatically extends to September 21 and then December 21 if specified regulatory conditions remain outstanding while the other applicable conditions are satisfied. The first-quarter timetable is therefore a target, not a contractual deadline.
The valuation also assumes integration benefits that do not exist at closing. The 11.5 times multiple includes the full $175 million annual synergy target expected by year three, making the multiple higher without those savings. Achieving the target requires successful integration, while regulatory remedies could reduce part of the strategic benefit. The buyer’s obligation to accept remedial actions is also subject to contractual limits.
Hedge Fund Sentiment
The filings available so far reflect positions held before Arcosa, Inc. shareholders approved the proposed transaction with CRH plc (NYSE:CRH). Insider Monkey’s database showed 40 hedge funds holding Arcosa, Inc. at the end of 2Q2026, up from 22 funds three months earlier.
Conclusion
The vote meaningfully de-risks the proposed acquisition by removing a required approval and confirming broad shareholder support. It does not secure a first-quarter 2027 closing. Regulatory clearance is now the dominant unresolved condition. Formal antitrust decisions, any required remedies, and subsequent execution against the $175 million synergy target will determine whether the transaction delivers on its timetable and valuation case.
READ NEXT: Guidewire (GWRE) Grew Fiscal 2026 ARR 19%. Can Cloud Economics Offset Slower Near-Term Growth? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center